

Isabelle Poizot-Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5113129/publications.pdf>

Version: 2024-02-01

49
papers

944
citations

516561

16
h-index

477173

29
g-index

54
all docs

54
docs citations

54
times ranked

1440
citing authors

#	ARTICLE	IF	CITATIONS
1	No increased risk of Kaposi sarcoma relapse in patients with controlled HIV infection after switching protease inhibitor-based antiretroviral therapy. <i>HIV Medicine</i> , 2022, 23, 301-306.	1.0	1
2	Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Data™AIDS Cohort. <i>Cancers</i> , 2022, 14, 401.	1.7	3
3	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma. <i>Cancers</i> , 2022, 14, 986.	1.7	5
4	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France. <i>PLoS ONE</i> , 2022, 17, e0261069.	1.1	4
5	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022, 208, 2663-2674.	0.4	8
6	Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network. <i>Bulletin Du Cancer</i> , 2021, 108, 908-914.	0.6	5
7	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	2.9	18
8	Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Data™AIDS Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 554-563.	1.1	21
9	Kaposi's Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition. <i>Cancers</i> , 2021, 13, 5702.	1.7	7
10	Determinants of Second Primary Cancer Type in Survivors of Virus-Related and Non-Virus-Related Cancer Living With HIV in the French Data™AIDS Cohort. <i>Cancer Control</i> , 2021, 28, 107327482110663.	0.7	0
11	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2435-2438.	2.9	17
12	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH). <i>Journal of Hepatology</i> , 2020, 72, 588-591.	1.8	7
13	Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015. <i>Aids</i> , 2020, 34, 569-577.	1.0	11
14	Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Data™AIDS Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2880-2888.	2.9	10
15	Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2020, 27, 1462-1472.	1.0	6
16	Kaposi sarcoma among people living with HIV in the French Data™AIDS cohort between 2010 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1065-1073.	1.3	4
17	HIV-infected patients' expectations about emotional and sexual health. <i>Sexologies</i> , 2019, 28, e7-e10.	0.5	1
18	Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH) - Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study. <i>HIV Medicine</i> , 2019, 20, 222-229.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Unsupervised PrEP in routine practice: a new challenge?. <i>International Journal of STD and AIDS</i> , 2019, 30, 715-717.	0.5	1
20	Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT ⁺ AIDS cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 278.	1.3	7
21	Immunotherapy for cancer in people living with HIV. <i>Aids</i> , 2019, 33, F13-F19.	1.0	61
22	HIV infection and care pathway: From guidelines to clinical practice. <i>Médecine Et Maladies Infectieuses</i> , 2019, 49, 23-33.	5.1	1
23	Consultation <i>«</i> Ant ⁺ sexuelle et affective <i>»</i> : quelles attentes pour les personnes vivant avec le VIH? <i>Sexologies</i> , 2019, 28, 20-24.	0.5	1
24	HIV is associated with airway obstruction. <i>Aids</i> , 2018, 32, 227-232.	1.0	22
25	Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. <i>PLoS ONE</i> , 2018, 13, e0203895.	1.1	50
26	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients <i>«</i> French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , 2017, 67, 23-31.	1.8	45
27	Frailty in HIV infected people. <i>Aids</i> , 2017, 31, 1573-1577.	1.0	17
28	Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. <i>HIV Medicine</i> , 2017, 18, 704-708.	1.0	45
29	Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients <i>«</i> <i>«</i> En route for eradication <i>»</i> ?. <i>Journal of Infection</i> , 2017, 75, 234-241.	1.7	17
30	Sub-therapeutic darunavir concentration and garlic consumption; a <i>«</i> Mediterranean <i>»</i> drug-food interaction, about 2 cases. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1331-1333.	0.8	5
31	Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3425-3434.	1.3	14
32	Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study. <i>PLoS ONE</i> , 2017, 12, e0187517.	1.1	9
33	A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.2	1
34	CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART. <i>PLoS ONE</i> , 2016, 11, e0165774.	1.1	21
35	From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 733-734.	0.8	3
36	Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV ⁺ hepatitis C virus coinfecting patients treated with boceprevir or telaprevir-based therapy. <i>Aids</i> , 2016, 30, 2085-2090.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. <i>HIV Clinical Trials</i> , 2016, 17, 63-71.	2.0	4
38	Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients. <i>Infectious Diseases</i> , 2016, 48, 392-398.	1.4	6
39	Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1644-1652.	0.5	9
40	Hepatitis C treatment initiation in HIV-HCV coinfecting patients. <i>BMC Infectious Diseases</i> , 2016, 16, 345.	1.3	8
41	ITPA deficiency and ribavirin level are still predictive of anaemia in HCV/HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). <i>Antiviral Therapy</i> , 2016, 22, 461-469.	0.6	0
42	First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.. <i>Medicine (United States)</i> , 2016, 95, e5087.	0.4	0
43	Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016, 213, 1455-1461.	1.9	28
44	Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0141164.	1.1	33
45	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , 2011, 118, 44-49.	0.6	62
46	The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. <i>International Journal of Cancer</i> , 2011, 129, 467-475.	2.3	77
47	Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1022-1029.	0.5	46
48	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30	1.3	79
49	A large French prospective cohort of HIV-infected patients: the Nadis Cohort. <i>HIV Medicine</i> , 2009, 10, 504-511.	1.0	118